AI-Generated Filing Summaries

Verde Resources established Verde Resources Asia Pacific Pte. Ltd. as a wholly owned subsidiary on March 30, 2026.

The subsidiary is incorporated in Singapore and follows discussions with Singapore's Economic Development Board and Land Transport Authority.

The move advances the company's strategy to license its Net Zero Blueprint and related technologies globally.

Stephen Hood appointed CEO effective March 27, 2026, via Motorsport Games Ltd with GBP 378,000 annual base salary and 50% target bonus.

Stanley Beckley appointed CFO effective March 27, 2026, with $300,000 annual base salary and 25% target bonus.

Hood reports to Board; Beckley reports to CEO and Board.

2026 Annual Meeting set for June 11, 2026 at 8:30 a.m. Pacific Time at principal executive offices in Los Angeles.

Stockholders of record as of April 17, 2026 close of business entitled to notice and vote.

Deadline for stockholder proposals and director nominations is 5:00 p.m. Pacific Time on April 12, 2026.

Operating losses widened significantly during the fiscal year, driven primarily by a surge in general and administrative expenses likely associated with post-IPO corporate structuring and compliance costs.

Operating cash burn accelerated, rapidly depleting liquidity resources and creating a deficit that overshadows the capital raised during the previous fiscal period's public offering.

The company's liquidity position deteriorated to a level that prompted auditor warnings regarding substantial doubt about the entity's ability to continue as a going concern.

Operating losses widened significantly during the fiscal year, driven primarily by a surge in general and administrative expenses likely associated with post-IPO corporate structuring and compliance costs.

Operating cash burn accelerated, rapidly depleting liquidity resources and creating a deficit that overshadows the capital raised during the previous fiscal period's public offering.

The company's liquidity position deteriorated to a level that prompted auditor warnings regarding substantial doubt about the entity's ability to continue as a going concern.

Revenues increased to RMB 206.0 million (US$29.5 million) for six months ended Dec 31, 2025, up RMB 59.6 million or 41% YoY.

Net income RMB 0.6 million (US$0.1 million) for H2 2025 vs net loss RMB 0.6 million prior year.

Acquired 51% of Zhonglian for RMB 25.5 million, paid RMB 8.2 million cash with RMB 17.3 million due by Oct 2026.

CEO Vlad Vitoc received a $312,610 one-time bonus for contributions to the recent capital raise — reflects direct linkage between executive compensation and financing success.

Head of Finance Jeffrey Himmelreich received a $50,000 one-time bonus — signals recognition of finance leadership in capital markets execution.

Bonuses were approved by the Board of Directors on March 27, 2026, and paid on March 31, 2026 — confirms timely, board-authorized compensation action.

Ms. Kapustina's employment ends on April 15, 2026 per Separation Agreement dated March 31, 2026.

Separation provides severance and benefits identical to her August 7, 2025 employment agreement.

Separation Agreement documented as Exhibit 10.1.

Propose carrying forward full EUR 6,901,677,892.10 balance sheet profit from 2025 financial year to new account.

Expand Supervisory Board from 6 to 8 members to enhance oncology, clinical development, and commercialization expertise amid strategic realignment.

Re-elect three current members (Helmut Jeggle, Prof. Dr. Anja Morawietz, Prof. Dr. Rudolf Staudigl) and elect two new (Dr. Susanne Schaffert, Prof. Dr. Iris Loew-Friedrich) to Supervisory Board.

Audit Committee reduced from three to two members effective April 1, 2026, due to Mary Rotunno’s resignation, triggering non-compliance with Nasdaq Listing Rule 5605(c)(2).

Non-compliance does not affect current listing of VTGN common stock on The Nasdaq Capital Market.

Company is granted a cure period expiring earlier of next annual meeting or one year from April 1, 2026 — or 180 days if annual meeting occurs by September 28, 2026.

Rhone Resch appointed Chief Strategy Officer, a newly created role reporting to CEO Takahiko Onozuka.

Resch to focus on U.S. market expansion, global manufacturing footprint, and solar value chain partnerships.

Over 20 years solar experience, including CEO of Solar Energy Industries Association (2004-2016).

Provides cloud-based preventative personal security platform with 14 app services and 24/7 command center agents, generating $9.97M revenue in 2025 (up 2.4% YoY).

S-1 registers 7.5M common shares for resale by Ascent (7.08M) and Maxim (0.42M), tied to $300M Equity Line SPA with 96% VWAP pricing and 9.99% ownership cap.

No proceeds to company from resale; reliant on equity line for funding amid $599K cash, $5.7M working capital deficit, and $10.5M 2025 net loss.

Acquired 80% of Tom Johnson Investment Management for $12.3 million, with $12 million paid in cash at closing.

TJIM manages approximately $1.63 billion in assets across equity and fixed income markets.

Principal seller retained 20% equity interest with put/call options exercisable after three years.

Company sold 2,857,144 shares of common stock at a price of $0.70 per share for gross proceeds of approximately $2.0 million.

Investors received unregistered warrants to purchase 2,857,144 shares at an exercise price of $0.85, exercisable in six months.

H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee and warrants to purchase 142,857 shares.

BD completed the spin-off of its Biosciences and Diagnostic Solutions business on February 9, 2026.

The spun-off business was combined with Waters Corporation as part of the transaction.

Exhibit 99.1 contains recast historical financials presenting the separated business as discontinued operations.

Amie Thuener O'Toole resigned as Vice President, Corporate Controller and Principal Accounting Officer, effective April 9, 2026.

Her resignation was voluntary and driven by pursuit of another professional opportunity, not any disagreement with the Company.

The role of Corporate Controller and Principal Accounting Officer is central to financial reporting integrity and SEC compliance.

Amie Thuener O'Toole resigned as Vice President, Corporate Controller and Principal Accounting Officer, effective April 9, 2026.

Her resignation was voluntary and driven by pursuit of another professional opportunity, not any disagreement with the Company.

The role of Corporate Controller and Principal Accounting Officer is central to financial reporting integrity and SEC compliance.

Re-appointment of co-founders Niels Riedemann (CEO) and Renfeng Guo (CSO) through 2030 confirms continuity in executive leadership and scientific strategy.

Board seeks extension of authority to acquire up to 10% of issued ordinary shares at ≤110% of 5-day average Nasdaq closing price — enabling flexible capital management.

Proposal to amend articles of association to increase authorized share capital supports future equity-based financing or compensation needs.

Vericel awarded 10-year BARDA contract valued at up to $197 million for NexoBrid, effective April 1, 2026.

Base period of $35 million includes $10 million over next 12 months for initial NexoBrid procurement and VMI establishment.

Contract covers U.S. Strategic National Stockpile expansion, blast trauma indication development, U.S. manufacturing facility, and room temperature stable formulation.

Jacqueline D. Reses resigns as Class I director effective immediately after 2026 AGM on or around May 21, 2026.

Board size to reduce from nine to eight members contingent on Reses' resignation post-2026 AGM.

BCP requests substitution of Amit Dalmia for Amit Dixit as Blackstone Designee Class II director at 2026 AGM.

Hamilton Re agreed to maintain a Minimum Commitment Amount of the lesser of $1.8 billion or 60% of the Group's net tangible assets.

The new agreement replaces and supersedes the Prior Commitment Agreement dated July 1, 2023, as amended, effective April 1, 2026.

A two-tier withdrawal structure was established: Sub-Series A (excess capital) allows quarterly withdrawals with 55 days' notice.

Business combination agreement with Veraxa Biotech AG signed April 22, 2025, amended twice through February 2026, indicating prolonged diligence.

IPO underwritten by Cantor Fitzgerald on August 8, 2024, with units trading as VACHU on Nasdaq, supporting ongoing trust account stability.

Adopted clawback policy Exhibit 97.1 on March 10, 2025, fulfilling Nasdaq/Dodd-Frank compliance ahead of any potential de-SPAC.

Business combination agreement with Veraxa Biotech AG signed April 22, 2025, amended twice through February 2026, indicating prolonged diligence.

IPO underwritten by Cantor Fitzgerald on August 8, 2024, with units trading as VACHU on Nasdaq, supporting ongoing trust account stability.

Adopted clawback policy Exhibit 97.1 on March 10, 2025, fulfilling Nasdaq/Dodd-Frank compliance ahead of any potential de-SPAC.

Meredith S. Weil, Board member and CFO, retiring effective January 2027 after nearly 30 years with Third Federal.

James E. LaRocca, 42, joins as Vice President and Finance and Accounting Officer of Third Federal on June 29, 2026.

LaRocca anticipated to succeed Weil as Company CFO upon her retirement.

Eric Sherb was appointed Chief Financial Officer, effective April 1, 2026, bringing 19 years of accounting and financial advisory experience.

The Company entered a Consulting Agreement with EMS Consulting Services, Inc., an entity controlled by Mr. Sherb, for outsourced CFO services.

Compensation includes a $5,000 monthly retainer and a one-time grant of 36,000 shares of common stock vesting over six months.

Revenue grew 18.1% to $17.2 billion, driven by growth in Advanced Solutions, Endpoint Solutions distribution portfolios, and Hyve Solutions.

Operating income increased 60.7% to $489.4 million, with operating margin expanding to 2.9% due to favorable product mix and increased operating leverage.

Net income nearly doubled, increasing 95.1% to $326.9 million, reflecting strong operating performance and disciplined expense management.

The company issued unregistered Series I and Series II shares for total aggregate net consideration of $28,284,860 on March 1, 2026.

A special cash distribution of $0.3399 per share was declared on March 31, 2026, payable on or about May 5, 2026 to holders of record on March 31, 2026.

The company increased its holdings in existing portfolio companies during March 2026.

Nasdaq notified the Company on March 27, 2026, that it failed to meet the $1.00 minimum bid price requirement by March 24, 2026, triggering a delist determination.

The Company received an initial non-compliance notice on September 25, 2025, after 30 consecutive business days below $1.00 per share.

The Company plans to file an appeal, which will stay any delisting action and filing of Form 25 pending the hearing panel’s decision.

Global leader in ice cream with 21% market share, operating in 80 countries via brands like Magnum, Ben & Jerry’s, and Cornetto.

Resale offering of 121,604,413 ordinary shares (19.86% of total) by Unilever subsidiaries; company receives no proceeds.

As of Dec 31, 2025, €441M cash, €3,416M total indebtedness, €625M shareholders’ equity.

Julia Rueb appointed as principal accounting officer effective April 1, 2026.

Alan Fuhrman succeeded as principal accounting officer but continues as principal financial officer.

Rueb has served as Vice President, Finance since January 2024 with prior accounting roles at SOAProjects and Ernst & Young.